DAIICHI SANKYO COMPANY, LIMITED Logo

DAIICHI SANKYO COMPANY, LIMITED

A global pharmaceutical firm developing novel therapies with a focus on oncology and ADCs.

4568 | T

Overview

Corporate Details

ISIN(s):
JP3475350009
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目5番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Daiichi Sankyo is a global pharmaceutical company focused on the research, development, and delivery of innovative medical solutions. The company's core business revolves around creating novel therapies, with a primary strategic focus on oncology. It is a leader in the science of antibody-drug conjugates (ADCs), a class of targeted cancer drugs. Beyond oncology, its portfolio and development pipeline include treatments for cardiovascular diseases and other specialty areas. The company manufactures and markets a range of prescription medicines, vaccines, and over-the-counter healthcare products, aiming to contribute to the enrichment of quality of life for patients worldwide by creating new standards of care.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 05:22
Registration Form
確認書
Japanese 8.2 KB
2025-11-07 05:19
Interim Report
半期報告書-第21期(2025/04/01-2026/03/31)
Japanese 321.7 KB
2025-10-10 02:55
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.2 KB
2025-10-03 04:15
Registration Form
発行登録追補書類(株券、社債券等)
Japanese 130.8 KB
2025-09-05 03:06
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.3 KB
2025-08-07 05:49
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.8 KB
2025-07-17 02:04
Registration Form
発行登録書(株券、社債券等)
Japanese 24.8 KB
2025-07-09 02:32
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.2 KB
2025-06-24 06:02
Registration Form
訂正発行登録書
Japanese 8.9 KB
2025-06-24 05:36
Post-Annual General Meeting Information
臨時報告書
Japanese 25.7 KB
2025-06-23 08:40
Registration Form
訂正発行登録書
Japanese 8.9 KB
2025-06-23 07:44
Share Issue/Capital Change
臨時報告書
Japanese 31.3 KB
2025-06-20 07:20
Governance Information
内部統制報告書-第20期(2024/04/01-2025/03/31)
Japanese 23.5 KB
2025-06-20 07:20
Registration Form
確認書
Japanese 8.1 KB
2025-06-20 07:19
Annual Report
有価証券報告書-第20期(2024/04/01-2025/03/31)
Japanese 3.0 MB

Automate Your Workflow. Get a real-time feed of all DAIICHI SANKYO COMPANY, LIMITED filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DAIICHI SANKYO COMPANY, LIMITED

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DAIICHI SANKYO COMPANY, LIMITED via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Clinical-stage biopharma developing novel cancer drugs aiming for fewer side effects.
Japan
4575
Candel Therapeutics, Inc. Logo
Developing off-the-shelf viral immunotherapies to help the immune system fight solid tumors.
United States of America
CADL
Can-Fite BioPharma Ltd. Logo
Develops oral small-molecule drugs targeting A3AR for oncology and inflammatory diseases.
Israel
CANF
Cannovum Cannabis AG Logo
Importer & producer of medical cannabis, expanding into recreational cultivation infrastructure.
Germany
27N0
Canopy Growth Corp Logo
Produces diverse cannabis products for medical and recreational markets globally.
United States of America
CGC
Cantourage Group SE Logo
A European platform producing and distributing medical cannabis products to pharmacies.
Germany
HIGH
CAPRICOR THERAPEUTICS, INC. Logo
Develops cell and exosome-based therapeutics for rare diseases like Duchenne muscular dystrophy.
United States of America
CAPR
CAREGEN CO.,LTD. Logo
Develops patented peptides and growth factors for medical aesthetics, pharma, and anti-aging markets.
South Korea
214370
Caribou Biosciences, Inc. Logo
Uses CRISPR genome editing to create off-the-shelf CAR-T cell therapies for cancer.
United States of America
CRBU
Carisma Therapeutics Inc. Logo
Developing engineered macrophage (CAR-M) therapies for solid tumors and autoimmune diseases.
United States of America
CARM

Talk to a Data Expert

Have a question? We'll get back to you promptly.